Analysts track a payer revolt against Sarepta’s controversial Duchenne drug
When the FDA’s Janet Woodcock pushed through a controversial approval for Sarepta’s Exondys 51 for Duchenne muscular dystrophy in September, she created a test …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
